The American Association of Clinical Oncology (ASCO) released a very important new policy statement that details their position surrounding the prescribing of opioids to cancer patients. This issue has taken the forefront of controversy as our society increasingly becomes concerned about the overuse of prescription opioids, sometimes leaving out the very specific needs of cancer [...]
Recently our long time partner, Patient Power (https://www.patientpower.info) has produced a number of videos that are of significant interest to all members of the prostate cancer community. Darryl Mitteldorf, Executive Director of Malecare talks about Malecare and what it does for men with cancer at: https://malecare.org Darryl Mitteldorf, founder of the National LGBT Cancer Project [...]
Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an [...]
I just returned, along with Malecare’s Executive Director Darryl Mitteldorf and Dr. Wendy Lebowitz, from the ASCO Genitourinary Cancers Symposium in San Francisco. The three of us often attend this meeting, but this one had a new and very special item, a research poster (abstract no. 253) that was presented by Malecare and Mitteldorf. The [...]
In the treatment of prostate cancer the first very expensive drug we had that was FDA approved was Provenge, with an initial cost of $93,000 for a one-month’s treatment protocol. Today, the cost is in excess of $106,000. According to the phase III clinical trial result Provenge extends life by a median of 4.1 months, [...]